Skip to main content

Advertisement

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis

Article metrics

  • 594 Accesses

Background

Published data from various regions evidenced that the administration of Etanercept (ET) restored auxological retardation attributed to the process of the chronic joint inflammation.

Aim

To assess the impact of ET on growth pattern in Greek JIA patients who had a resistant poly- or an oligoarthritis. Methods: Data of 24 JIA patients (F:M 19:5, 20/24 with a polyarthritis) who had received ET at a median age of 6.7 yrs (1.9-14.5 yrs) escorted by their auxological parameters were collected. Standard Deviation Scores for Height (HSDS) and Body Mass Index (BMISDS) were calculated according to sex- and age- matched percentiles of the healthy Greek population, 2 and 1 yrs pre-ET treatment, and 1 and 2 yrs thereafter. Growth velocity was defined as the change in Height SDS (ΔHSDS) and in BMI (ΔBMISDS) and compared to the time of ET initiation (baseline).

Results

At baseline 16/24 pts had a growth retardation (median ΔHSDS –0.56); 11/16 showed a significant increase 1yr post-treatment (ΔHSDS +0.29, p<0.001) which did not further increase (2nd yr: ΔHSDS +0.15). Similarly, at baseline, BMI was retarded in 14/24 pts (median ΔBMISDS-0.6); in 10/14, BMI increased 1 and 2 yrs post-ET (ΔBMISDS +0.31, +0.12 respectively, p<0.001) and remained stable thereafter. Growth and BMI improvements were not associated either with age of ET initiation, or gender, or presence of ANA, or disease duration, or JIA course or MDVAS.

Conclusion

ET treatment can restore the linear growth and BMI of JIA patients irrespectively of their demographic or clinical profile.

Author information

Correspondence to M Trachana.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Trachana, M., Triantafyllou, P., Vraka, A. et al. The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis. Pediatr Rheumatol 9, P149 (2011) doi:10.1186/1546-0096-9-S1-P149

Download citation

Keywords

  • Body Mass Index
  • Arthritis
  • Growth Pattern
  • Disease Duration
  • Etanercept